Merck, Inc.
🇺🇸United States
AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00122343
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
Phase 1
Completed
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2010-06-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00120835
Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy
Phase 2
Completed
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2010-06-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00120861
A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C
Phase 2
Completed
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2009-03-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 175
- Registration Number
- NCT00118768
MARS - Monitored Atherosclerosis Regression Study
Phase 2
Completed
- Conditions
- AtherosclerosisCoronary Artery Disease
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2009-12-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 270
- Registration Number
- NCT00116870
- Locations
- 🇺🇸
Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine, Los Angeles, California, United States
Study to Treat Uveitis Associated Macular Edema
Phase 2
Terminated
- Conditions
- Cystoid Macular EdemaUveitis
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00114062
Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 147
- Registration Number
- NCT00112372
A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)
Phase 2
Completed
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 399
- Registration Number
- NCT00112437
An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)
Phase 2
Completed
- Conditions
- Dyslipidemia
- First Posted Date
- 2005-05-27
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 575
- Registration Number
- NCT00111891
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
- First Posted Date
- 2005-05-26
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT00111813
© Copyright 2025. All Rights Reserved by MedPath